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AbsTrACT
Introduction Multimorbidity is a health issue of increasing 
importance worldwide, and is likely to become particularly 
problematic in low- income countries (LICs) as they 
undergo economic, demographic and epidemiological 
transitions. Knowledge of the burden and consequences 
of multimorbidity in LICs is needed to inform appropriate 
interventions.
Methods A cross- sectional household survey collected 
data on morbidities and frailty, disability, quality of life 
and physical performance on individuals aged over 40 
years of age living in the Nouna Health and Demographic 
Surveillance System area in northwestern Burkina Faso. 
We defined multimorbidity as the occurrence of two or 
more conditions, and evaluated the prevalence of and 
whether this was concordant (conditions in the same 
morbidity domain of communicable, non- communicable 
diseases (NCDs) or mental health (MH)) or discordant 
(conditions in different morbidity domains) multimorbidity. 
Finally, we fitted multivariable regression models to 
determine associated factors and consequences of 
multimorbidity.
results Multimorbidity was present in 22.8 (95% 
CI, 21.4 to 24.2) of the study population; it was more 
common in females, those who are older, single, more 
educated, and wealthier. We found a similar prevalence 
of discordant 11.1 (95% CI, 10.1 to 12.2) and concordant 
multimorbidity 11.7 (95% CI, 10.6 to 12.8). After controlling 
for age, sex, marital status, education, and wealth, an 
increasing number of conditions was strongly associated 
with frailty, disability, low quality of life, and poor physical 
performance. We found no difference in the association 
between concordant and discordant multimorbidity 
and outcomes, however people who were multimorbid 
with NCDs alone had better outcomes than those with 
multimorbidity with NCDs and MH disorders or MH 
multimorbidity alone.
Conclusions Multimorbidity is prevalent in this poor, rural 
population and is associated with markers of decreased 
physical performance and quality of life. Preventative and 
management interventions are needed to ensure that 
health systems can deal with increasing multimorbidity 
and its downstream consequences.
InTroduCTIon
Over the past decades, there has been substan-
tial progress in reducing infectious disease- 
related morbidity and improving maternal 
Key questions
What is already known?
 ► Multimorbidity is an increasing health problem 
worldwide, but the burden in many low income, and 
particularly the least developed, countries remains 
unknown.
 ► How multimorbidity relates to functional outcomes 
and quality of life in people living in these regions 
has not been well documented; there is very little 
evidence from least developed countries.
What are the new findings?
 ► In Burkina Faso, one of the poorest countries in the 
world, multimorbidity, defined as two or more condi-
tions, is present in over 20% of those aged over 40 
in a rural population.
 ► Multimorbidity prevalence increases with age, is 
more common in women, in those who have more 
education, are unmarried or are in the highest rela-
tive economic category.
 ► Increasing numbers of morbidities are associated 
with frailty, disability, lower quality of life and poorer 
physical performance.
 ► People who are multimorbid with non- communicable 
diseases (NCDs) alone have better outcomes than 
those who those who have concurrent NCDs and 
mental health conditions or are multimorbid with 
mental health conditions alone.
What do the new findings imply?
 ► Multimorbidity is a global health issue of major sig-
nificance requiring substantial investment in health 
system funding to combat.
 ► Adopting a more holistic care provision strategy, 
instead of siloed care, could provide an avenue to-
wards better health.
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and child health.1–3 These successful efforts, combined 
with rapid economic development, have resulted in an 
ageing population in low- income and middle- income 
countries (LMICs), and especially in ub- Saharan Africa.4 5 
New disease and mortality patterns have accompanied 
these transitions and non- communicable diseases (NCD) 
and mental health (MH) disorders have emerged as 
important issues.6–8 A change in development focus has 
paralleled this epidemiological shift with the sustainable 
development goals moving away from single diseases, to 
a broader array of conditions and access to the health 
systems required to treat these.9 These changes have 
come with a realisation that individuals often suffer from 
multiple concurrent conditions, and that the circum-
stances in which individuals live impacts both risk of 
conditions and their physical consequences.10 11
Although there have been studies on multimorbidity in 
lower- middle income countries most of them have been 
done in upper- middle income countries. In sub- Saharan 
Africa, these have mainly been conducted in South 
Africa,12 13 which is an upper- middle- income country 
with a relatively well- developed health system.14 There is 
very little information about who is affected by multimor-
bidity in other countries in sub- Saharan Africa, where 
many of the least developed countries with the world’s 
poorest populations and most under- resourced health 
systems are found.
Similarly, there are few data on associations between 
multimorbidity prevalence and patterns and related 
health outcomes in the least developed countries, 
although studies have shown associations with hospital-
isations, mortality, disability, low quality of life and poor 
physical performance in other, more developed coun-
tries, countries.15–24 Given the differences in context, 
including wealth, culture and health service availability, 
it cannot be assumed that relationships between multi-
morbidity and outcomes found in upper or upper- middle 
income countries apply to lower income countries (LICs). 
The increase in the triple burdens of communicable, 
NCD and MH in LICs means such information is essen-
tial to inform investment in preventative and manage-
ment initiatives, and to shape the development of health 
systems in these least developed countries.25
Importantly, a meaningful definition of multimorbidity 
that aligns the concept with patient outcomes, rather 
than based solely on expert opinion, has also not been 
agreed on.6 20 22 26–28 The WHO defines multimorbidity 
as the coexistence of two or more chronic conditions.29 
However, it has also been described as the count of condi-
tions, two or more conditions in the disease domains of 
communicable, non- communicable or MH, and has been 
further subdivided into discordant (more than two condi-
tions in different domains) or concordant (more than 
two conditions in the same domain) multimorbidity.6 13 
Showing the relationships between multimorbidity using 
these definitions and functional outcomes in one of the 
poorest countries in the world is useful to policy makers, 
funders and researchers.
Burkina Faso is a small landlocked LIC in sub- Saharan 
Africa with limited natural resources; it is ranked 183 
of 189 countries on the Human Development Index.30 
It has a population of about 19 million people which is 
growing rapidly.30 31 There are few data on the epidemi-
ology of multimorbidity in Burkina Faso, although one 
study suggested a high prevalence of multimorbidity 
in an urban setting.32 This study aims to investigate the 
prevalence and associations (including important down-
stream consequences of multimorbidity including frailty, 
disability, quality of life and other measures of physical 
performance) among middle- aged and older individuals 
in a rural, very low income setting in Burkina Faso. We 
sought to assess the prevalence of multimorbidity, both 
with concordant conditions (defined as two or more 
conditions in the same morbidity domain of communi-
cable, NCD or MH) and discordant conditions (defined 
as two or more conditions in different morbidity 
domains) in rural Burkina Faso, explore how multimor-
bidity varies by sociodemographic characteristics in this 
population and to assess whether it is correlated with 
related outcomes such as frailty, disability, low quality of 
life and poor physical performance.
MeTHods
study setting
The study was set in the Nouna Health and Demographic 
Surveillance System (HDSS) area, led by the Centre 
de Recherche en Santé de Nouna (CRSN). The HDSS 
collects data, yearly, on births, deaths and migration in a 
well- enumerated population in the Boucle du Mouhoun 
region, north- western Burkina Faso. The demographic 
surveillance area of the Nouna HDSS consist of the 
market town of Nouna and 59 surrounding villages with 
a total population of 107 000.33 Residents come from 
multiple ethnic groups (Bwaba, Dafin, Mossi, Peulh and 
Samo) and have a range of religious beliefs (Animist, 
Muslim, Protestant and Roman Catholic). The major 
economic activities are farming and animal husbandry.
sample
Data for this cross- sectional study were obtained during 
the baseline wave of the CRSN Heidelberg Aging Study 
(CHAS). CHAS consists of a population- representative 
sample of adults ≥40 years of age living in the Nouna HDSS 
area. To obtain a sample of 3000 older adults, we used a 
two- part multistage random sample of 4000 individuals 
from the 2015 Nouna HDSS census, allowing for 25% loss 
due to mortality, mobility or non- response. The sample 
size of 3000 was chosen to detect meaningful differences 
in the prevalence of hypertension and diabetes across 
key demographic and lifestyle factors. In all villages with 
fewer than 90 adults aged over 40, all adults were selected 
to take part. In all other villages, a random sample of 
households with at least one person over 40 years old 
was drawn, and then within each selected household one 
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age- eligible adult was randomly selected to complete the 
survey.
data collection
Data collection was performed between May and July 
2018. Data were collected using Open Data Kit software 
on tablet computers at the participants’ residence.34 
Interviews were conducted in either French or translated 
by the interviews into the local languages of Dioula or 
Mooré. The household survey questionnaire contained 
questions on age; gender; education; marital status; 
household assets and self- reported medical conditions. 
Cognition was assessed using the eight question commu-
nity screening interview for dementia (CSI- D),35 anxiety 
using the Generalised Anxiety Disorder question (GAD-2) 
score36 and depression using Patient Health Question-
naire (PHQ-9).37 38 Questions on weight loss in the past 
year, self- reported activity and levels of exhaustion were 
used in construction of the Fried frailty score.39 40
Height and weight were measured using generic scales 
and measurement bands against a vertical and hori-
zontal smooth surface, respectively. Blood pressure was 
measured in a seated position in the left arm after 15 min 
rest; three measures were taken using Omron Series 7 
portable blood pressure machines (Omron Healthcare, 
Kyoto, Japan) with the second and third measurements 
taken at least 5 min apart. The mean of the second and 
third measurements was used in analyses. Capillary 
glucose levels were analysed using SD Biosure Codefree 
point- of- care testing strips, and cholesterol using the 
Jactron Pictus 400 machine. Three measures of physical 
performance were obtained. Chair rise was measured by 
recording the time taken to make five rises from a stan-
dardised collapsible armless chair using a digital stop-
watch; participants were asked to stand without using 
their arms to assist.41 Walk speed was measured over a 
4- m course marked out on level ground.41 Participants 
were asked to walk their regular pace from a standing 
start. Two measures were taken, doing the course in each 
direction, and time was taken using a digital stopwatch 
and recorded to the nearest tenth of a second. The fastest 
speed in metres per second (m/s) was used. Hand grip 
strength was measured using a Jamar Hydraulic Hand 
Dynamometer.42 Measurements were taken with the 
participant seated, the arm at 90º elbow flexion and the 
shoulder and wrist in the neutral position. Two attempts 
were recorded from each hand; the maximum was used 
in this analysis.
definition of variables
Demographic characteristics
Marital status was categorised as married/cohabiting or 
single/widowed/divorced. Educational level was catego-
rised as no education or any education. Participants were 
asked 37 questions on household assets and dwelling 
characteristics; from these, wealth quintiles were derived 
from the first principal component using the method of 
Filmer and Pritchett.43
Definitions of disease states
A prior diagnosis of cancer, HIV, chronic respiratory 
disease, stroke and heart disease relied on self- report of 
diagnosis (eg, ‘Have you ever been told by a health worker 
that you have cancer?’). Hypertension was defined as 
either self- reported previous diagnosis or currently being 
on treatment, or as a measured systolic blood pressure 
≥140 mm/Hg, or a diastolic blood pressure ≥90 mm/
Hg. Diabetes was defined as either self- reported diag-
nosis; being on treatment; a non- fasting point of care 
capillary glucose level >200 mg/dL, HbA1c>6.5% or 
fasting glucose >126 mg/dL. Hypercholesterolaemia was 
defined as a total plasma cholesterol >200 mg/dL, low 
density lipoprotein >160 mg/dL, or self- reported diag-
nosis or treatment.
Participants were defined as having symptoms of anxiety 
based on a GAD-2 score ≥3.36 Participants scoring 0–4 on 
PHQ-9 were defined as no depressive symptoms, those 
scoring 5–9 mild depressive symptoms, 10–14 moderate 
depressive symptoms, 15–19 moderate- severe depressive 
symptoms and ≥20 severe depressive symptoms; we cate-
gorised participants with moderate or greater symptoms 
as having depressive symptoms in this analysis.38 Cognitive 
functioning was measured using Community Screeing 
Instrument for Dementia (CSI- D) with a maximum score 
of nine, and divided into normal or possible/probable 
cognitive impairment if a score under seven.44
The Fried score was used to calculate frailty using the 
original five domains (weight loss, low grip strength, walk 
speed, activity levels and exhaustion). We chose to use the 
Fried score to calculate frailty as it can easily be deployed 
in a low resource setting, given that it uses just five param-
eters.12 39 The Fried score is a validated method which is 
shown to be feasible and comparable to other methods 
for calculating frailty.45 46 Cut- offs for each domain of 
frailty were selected to be as close to the original Fried 
frailty score as possible (detailed definitions published 
elsewhere).39 Weight loss was defined as self- reported loss 
of >4 kg over the last 12 months, low grip strength as the 
lowest quintile of BMI- adjusted grip for each sex and low 
walk speed as the lowest quintile of height- adjusted walk 
speed over a 4- m course for each sex. Low activity levels 
were defined as the highest quintile of self- reported hours 
of sitting per week for each sex. Self- reported exhaustion 
was measured using two questions from the Center for 
Epidemiologic Studies Depression Scale (CES- D) scale: 
‘Everything I did in the last week was an effort’ or ‘I could 
not get going’.47 A positive response was defined as either 
statement applying for at least 3–4 days per week.
Each domain (low grip strength, low walk speed, 
or self- reported weight loss, exhaustion or low activity 
levels) scored 1 point giving a final total between 0 and 
5 points. Individuals were categorised as non- frail/robust 
(0 points), prefrail (1–2 points) or frail (3–5 points). 
Participants with missing data in one or more domains 
were labelled as ‘as unable to calculate’; previous work in 
South Africa has suggested that such individuals have a 
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health prognosis similar to or worse than those classified 
as frail, therefore they were included in frail category.46
Disability was measured using the 12- item WHO 
Disability Assessment Schedule, version 2 (WHODAS 
V.2.0) disability score.11 48 This score measures impair-
ments in function, activity and participation (mobility, 
self- care, cognition, interaction with others, life activi-
ties and social participation). Measures were summed to 
form a score, then normalised to a 0–100 scale, where 
0 equals no disability and 100 represents the worst 
disability. Quality of life was measured using the vali-
dated EuroHIS 8- item version of the WHO Quality of 
Life (WHOQOL).11 49 Each item was scored on a five- 
point scale and summed: for the analysis, the score was 
normalised to a 0–100 scale, with 100 denoting the best 
quality of life.
Defining multimorbidity
First, count of morbidities (regardless of domain) was 
described. Then, morbidities were categorised into 
seven groups within three domains as follows: Non- 
communicable: Cardiovascular (hypertension, diabetes, 
hypercholesterolaemia, heart disease or stroke), chronic 
respiratory disease (chronic pulmonary obstructive 
disease or asthma) or cancer. Communicable: prior HIV. 
Mental Health: cognitive impairment, or symptoms of 
anxiety or symptoms of depression. Multimorbidity was 
defined as presence of two or more conditions (regard-
less of domain); two or more conditions, with at least one 
in a different domain (discordant multimorbidity); or 
two or more conditions that are all in the same domain 
(concordant multimorbidity). Given multimorbidity with 
NCDs alone has been associated with better outcomes 
than with NCDs and MH, a separate analysis was done 
looking at associations of multimorbidity with NCDs, MH 
or both with functional outcomes.6 50 Since some of the 
conditions are self- reported, a separate sensitivity anal-
ysis was done using only objective measurements which 
included six conditions (hypertension, diabetes, hyper-
cholesterolemia, cognitive impairment, symptoms of 
anxiety or symptoms of depression).
Patient and public involvement statement
Participants were not directly involved in planning the 
study as it was done as a part of regular demographic 
health survey. Information was regularly fed back to the 
participants as by protocol for a demographic health 
survey.
statistical analysis
All analyses were done using SPSS V.24. Variables were 
described using mean and SD, or median and IQR if 
not normally distributed. Categorical variables were 
described using count and proportion. Only participants 
with data on all the outcome variables were included in 
the analysis. Bivariate associations between individual 
morbidities or morbidity categories and functioning 
outcomes were tested using the χ2 test for categorical 
variables and student’s t- test or Mann- Whitney- U for 
normally or non- normally distributed continuous vari-
ables, respectively. Multivariable models were fit using 
general linear modelling using a gamma distribution and 
a log link for skewed dependent variables. We present OR 
and 95% CIs, estimated marginal means (EM) and beta 
values with standards errors, where appropriate. Inverse 
probability of response weights for survey participation 
were calculated using gender- specific logistic models for 
study participation given sample selection. The model 
included age category, religion, ethnicity and village, and 
we used these weights in all analyses. Of note, 95.3% of 
households supplied only one person to take part in the 
survey; we therefore assumed clustering at the household 
level to be minimal and did not adjust for it.
resulTs
Of the 3998 sampled individuals, 3033 agreed to partic-
ipate and completed a study questionnaire. Only partic-
ipants with information on all conditions were included 
leaving us with a sample of 2604 (85.9%) people in our 
analysis. Missing data on HIV status was the most common 
reason for exclusion (n=218). There was no significant 
difference between the included individuals and those 
that were excluded due to missing values (online supple-
mentary appendix table 1). Weighted proportions for 
all variables used in the study are presented in table 1. 
Notably, 50.1% of the study population were women, a 
most participants were aged between 40 and 49 (41.7%), 
92.5% had no formal education and 74.9% were married 
or cohabiting; 48.8% (95% CI 16.7 to 34.2) of the popu-
lation had at least one NCD, with hypertension being the 
most prevalent (36.7%, 35.2 to 38.4), while 0.6% (0.04 
to 0.09) had a communicable disease, and 21.1% (77.6 
to 80.3) had symptoms suggestive of any MH. Approxi-
mately half (47.8%, 46.1 to 49.6) of the population was 
prefrail and 8.0% (7.1 to 9.0) were frail, the median disa-
bility score was 8.3 (IQR 0.0–22.9) and the mean quality 
of life score was 59.97 (SD 14.4). Almost one- quarter 22.8 
(21.4 to 24.2) of respondents were multimorbidity using 
the liberal definition of two or more conditions, where 
half of them had concordant (11.7%, 10.6 to 12.8) and 
half had discordant (11.1%, 10.1 to 12.2) multimorbidity; 
9.3% (8.4 to 10.4) had multimorbidity with only NCDs, 
while 2.5% (2.04 to 3.09) had multimorbidity with only 
MH and 10.9% (9.9 to 12.0) had multimorbidity with 
both MH and NCDs.
Multivariable associations between population char-
acteristics; morbidity domain of NCD, communicable 
disease or MH; or multimorbidity category of two 
or more conditions, discordant or concordant are 
presented in table 2 (bivariate associations are shown in 
online supplementary appendix table 2). Associations 
with increasing numbers of conditions are also shown. 
Female sex; increasing age; increasing education level; or 
increasing wealth; or being widowed, single or divorced 
were associated with a greater number of conditions, 
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Table 1 Weighted proportions of demographic characteristics and outcomes of included study participants (n=2604)
Parameter Group % of population unless stated
Female 50.1
Age 40–49 41.7
50–59 27.7
60–69 18
70–79 10.2
80+ 2.5
Education level No completed education 92.5
Some education 7.5
Marital status Widowed/divorced/single 25.1
Married/cohabiting 74.9
Wealth quintile (5 is the most wealthy) 1 19.5
2 19.7
3 19.3
4 20.8
5 20.7
Non- communicable diseases Hypertension 36.7
Diabetes 6.7
Hypercholesterolaemia 10.9
Heart disease 5.7
Stroke 1.2
Chronic respiratory disease 3.2
Cancer 0.5
Proportion of people with at least 1 NCD 48.8
Communicable disease HIV 0.6
Proportion of people with at least 1 CD 0.6
Mental health Cognitive impairment on testing 7.1
Symptoms of anxiety on testing 12.4
Depressive symptoms on testing 7.9
Proportion of people with at least 1 MH 21.1
Frailty Not frail 44.2
Prefrail 47.8
Frail 8.0
Disability WHO DAS score (0–100) median (IQR) 8.33 (0–22.92)
Quality of life WHO QoL score (0–100) mean (SD) 59.97 (14.43)
Physical functioning Chair rise time (s) median (IQR) 14.00 (11.99–17.00)
(179 missing)
4- m walk speed (m/s) mean (SD) 0.96 (0.26)
(32 missing)
Grip strength mean (SD) 37.88 (11.32)
Multimorbidity categorisation Count >2 22.8
Count >3 8.0
Count >4 2.4
Multimorbidity categorisation Concordant (>2 conditions with each in the same 
category)
11.7
Discordant (>2 conditions with each in different 
categories)
11.1
CD, communicable disease; DAS, Disability Assessment Schedule; MH, mental health; NCD, non- communicable disease; QoL, quality of life.
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and all of them except marital status were also associ-
ated with being multimorbid (>2 conditions). Women 
were more likely than men to have a condition in the 
domains of NCD or MH, but there was no association 
between sex and communicable diseases. Women were 
also more likely than men to be multimorbid whether 
concordant or discordant. Increasing age was associated 
with increased likelihood of having morbidities in the 
NCD or MH domains, or being multimorbid, whether 
concordant or discordant. Longer length of education 
was associated with a greater likelihood of having NCDs, 
and greater likelihood of concordant multimorbidity. On 
the other hand, people with some education were less 
likely of having MH symptoms. Higher wealth was posi-
tively associated with NCDs and concordant multimor-
bidity, but negatively associated with MH symptoms. In 
the sensitivity analysis only using objective measurements 
female gender remained associated NCDs, MH, increased 
number of conditions and having concordant or discor-
dant multimorbidity. Age continued to be positively 
associated with having a NCD, MH, increased number 
of conditions and multimorbidity (concordant or discor-
dant). Similarly, education was associated with higher 
likelihood of NCDs, but lower risk of MH, and an all over 
higher risk of having concordant multimorbidity (online 
supplementary appendix table 3). Wealth was associated 
with NCDs and concordant multimorbidity, but only the 
lowest wealth quintile had a significantly increased risk 
of having MH (online supplementary appendix table 3). 
Associations between individual characteristics and being 
multimorbid in the domains of NCDs and MH can be 
seen in online supplementary appendix table 4. Women 
were more likely to have multimorbidity with NCDs, or 
multimorbidity with NCDs and MH, but not multimor-
bidity with only MH conditions. Age was associated with 
multimorbidity in either category of NCDs, MH or NCD 
and MH together. Education was associated with a higher 
risk of having multimorbidity with NCDs, but lower risk 
of having multimorbidity with MH, and there was no 
association of with education and having multimorbidity 
with NCDs and MH. Increasing wealth was associated 
with having multimorbidity with NCDs, but not with MH, 
nor having multimorbidity with NCDs and MH.
In multivariable analyses, having a greater number 
of conditions was substantially and significantly associ-
ated with a greater prevalence of frailty, worse disability, 
worse quality of life and slower walk speed, but not time 
to chair rise or grip strength, when controlling for sex, 
age, education level, marital status and wealth (table 3). 
Multimorbidity defined as two or more conditions was 
significantly associated with a greater prevalence of 
frailty, worse disability, worse quality of life and poorer 
physical performance expect for hand grip strength 
(table 4). In figure 1, the relationship between increasing 
age and multimorbidity with frailty (figure 1A), disability 
(figure 1B) and quality of life (figure 1C) is shown. Both 
discordant and concordant multimorbidity were associ-
ated with a greater prevalence of frailty, worse disability, 
worse quality of life and lower walk- speed, but not time 
to chair rise or grip strength (online supplementary 
appendix table 5). Discordant multimorbidity was also 
more strongly associated with a higher prevalence of 
frailty, higher disability score and worse quality of life 
than concordant multimorbidity (online supplemen-
tary appendix table 5), however, differences were non- 
significant when adjusting for number of conditions 
in the multivariable analysis (table 5). Compared with 
being multimorbid in the domain of NCDs alone, multi-
morbidity in the domains of MH, or multimorbidity with 
MH and NCDs was associated with greater frailty, higher 
disability scores, lower quality of life, lower walk speed 
and lower hand grip strength (online supplementary 
appendix table 6). Proportions and overlap between 
people with NCDs, MH or communicable diseases are 
shown in figure 2. Only 0.1% had a condition in all three 
disease domains.
dIsCussIon
This study has shown that in rural Burkina Faso, multi-
morbidity, defined as two or more conditions, is common, 
and present in nearly one quarter of the population over 
40 years old. Multimorbidity is more common in women, 
among those who are older, those who have formal 
education, unmarried individuals and those of relatively 
higher economic status. Although limited by the number 
of conditions that we could collect, we found that 
discordant multimorbidity was as common as concordant 
multimorbidity, highlighting that patterns of multimor-
bidity are complex in this population. Multimorbidity was 
independently associated with a greater prevalence of 
frailty, worse disability, lower quality of life and lower walk 
speed. There was no significant difference between those 
with discordant versus concordant multimorbidity, after 
adjustment for number of conditions. However, multi-
morbidity with MH alone, or multimorbidity with MH 
and NCDs had worse measurements for all outcomes, 
except from time to chair rise, compared with multimor-
bidity with only NCDs.
Multimorbidity is a little- explored topic in low- resource 
settings18 and this is one of the first papers reporting the 
prevalence of multimorbidity such settings. There has 
been one previous study from Burkina Faso, conducted 
in a major city in 2010, which found an even higher 
prevalence of multimorbidity (65%) than in this study.32 
However, the earlier study population was older (>60 
years of age) and data were collected on a wider range 
of conditions, many of which were highly prevalent (eg, 
osteoarthritis), and which encompassed a range of health 
states somewhat broader than our definition of a disease 
(eg, visual impairment, malnutrition). In our sample, the 
prevalence of multimorbidity was higher (35.2%) among 
those of 60 years of age compared with younger adults, 
but not nearly as high as in the previous study from 
Burkina Faso. Thus, it is possible either that our results 
underestimate the prevalence of broad multimorbidity in 
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Figure 1 Frailty, disability score (WHODAS) and quality 
of life score (WHOQOL) according to age group and 
multimorbidity.
rural Burkina Faso, or that previous work overestimated 
the prevalence, depending on the definition of what 
constitutes a disease that is adopted.
We are not aware of any previous study that has looked 
at the patterns (or morbidity domains in which disease 
is occurring) of multimorbidity or ascertained its associ-
ations with frailty, disability, quality of life and physical 
performance in West Africa or other LICs defined as least 
developed. Our findings are of particular importance, 
because, although we cannot demonstrate causality in 
this cross- sectional study, it highlights that multimorbidity 
is at least associated with important health and well- being 
consequences, including limitations in physical function 
and decreased self- reported quality of life.
Knowledge of who suffers from multimorbidity and 
how morbidities are grouped can help with the design of 
healthcare services to treat the multimorbid patient, and 
support in the development of guidelines for healthcare 
practitioners of which other conditions to look for when 
a person presents with a single disease.
In contrast to findings from high- income coun-
tries,22 51 52 our study has found that even when controlling 
for age, wealthier people are more likely to have multi-
morbidity than those who are poorer, this is especially 
the case for multimorbidity with NCDs. This may reflect 
the shifting patterns of diseases and risk factors with 
individual wealth seen as countries’ gross domestic 
product improves.53 Obesity in particular affects those 
who are relatively wealthy in LICs and LMICs and asso-
ciated cardiometabolic diseases affect the highest wealth 
quintile.53 The findings may also reflect that wealthy 
people have better access to healthcare and are more 
likely to have their conditions diagnosed,52 54 although 
work has shown that healthcare access is universally poor 
in LICs.55 56 While we have found that the socioeconomic 
associations with multimorbidity in this low- income 
country are different to those seen in high- income coun-
tries, we have shown that the associations in terms of 
functional outcomes are similar across socioeconomic 
strata. Thus, ultimately, the meaning of multimorbidity 
in terms of consequences to the patients, the healthcare 
system which treats them and the families that care for 
them, is likely to be similar no matter what income level 
patients come from.
We have shown that in this population, having two or 
more conditions in the discordant multimorbidity cate-
gory is just as likely as having two or more conditions in 
the same domain; thus, in healthcare structures that have 
hitherto provided siloed care, adopting a more holistic 
care provision strategy could provide an avenue towards 
better health. The high prevalence of discordant multi-
morbidity highlights that such approaches cannot be 
limited to the management of concordant clusters of 
morbidities, such as diabetes, hypertension and dyslip-
idaemia; such an approach has failed to provide effec-
tive, joined- up care in high- income countries,57 and 
replicating this model in developing countries would 
therefore be a missed opportunity. However, because 
the number of conditions we investigated in this study 
were limited, we were unable to conduct a more nuanced 
cluster analysis.
Frailty, disability and reduced quality of life are strongly 
and independently associated with increasing number of 
conditions. However, these findings also indicate that 
discordant multimorbidity is no different to concordant 
multimorbidity in its association with poor individual 
outcomes, when controlling for number of conditions. 
This is in contrast with what has been found previously 
with patients with discordant multimorbidities typically 
having poorer health- related quality of life and worse 
clinical outcomes.6 13 58 Interestingly, we found that 
people who have multimorbidity with only MH condi-
tions or multimorbidity with MH conditions and NCDs 
have worse outcomes than those with only NCDs. The 
finding that people with NCDs and MH have worse 
outcomes than those with NCDs alone has been found 
in other countries, including high income countries 
(HICs).6 However, our findings suggest that those with 
multimorbidity in the domain of MH alone were the 
worse off in terms of outcomes that we assessed. A reason 
for this could be that people with NCDs have greater 
access to healthcare and have their needs addressed 
more thoroughly than people with MH conditions.59 A 
previous paper from South Africa found that patterns of 
multimorbidity affect healthcare utilisation, potentially 
supporting our hypothesis;13 however, this finding needs 
to be explored in further studies.
It is not possible from this cross- sectional analysis to 
know if the relationship between increasing numbers of 
morbidities and frailty, disability, low quality of life and 
poor physical performance is causal. However, given life 
expectancy in Burkina Faso increased from 49.5 in 1990 
to 60.8 in 2017,31 knowledge of high prevalence of multi-
morbidity and these associations is cause for concern in a 
growing population with few healthcare resources.
Hence, preventative and management interventions 
needs to be done in order to ensure that the health 
copyright.
 o
n
 M
ay 28, 2020 at Barnes Library M
edical School. Protected by
http://gh.bmj.com/
BM
J G
lob Health: first published as 10.1136/bmjgh-2019-002096 on 29 March 2020. Downloaded from 
Odland ML, et al. BMJ Global Health 2020;5:e002096. doi:10.1136/bmjgh-2019-002096 11
BMJ Global Health
Ta
b
le
 5
 
M
ul
tiv
ar
ia
b
le
 a
ss
oc
ia
tio
ns
 b
et
w
ee
n 
m
ul
tim
or
b
id
ity
 c
at
eg
or
y 
an
d
 fr
ai
lty
, d
is
ab
ili
ty
, q
ua
lit
y 
of
 li
fe
 a
nd
 m
ea
su
re
m
en
ts
 o
f p
hy
si
ca
l p
er
fo
m
an
ce
s 
af
te
r 
ad
ju
st
in
g 
fo
r 
nu
m
b
er
 o
f c
on
d
iti
on
s
O
ut
co
m
e
Va
ri
ab
le
G
ro
up
Fr
ai
l o
r 
un
ab
le
W
ho
 D
A
S
Q
ua
lit
y 
o
f 
lif
e
T
im
e 
to
 c
ha
ir
 r
is
e
W
al
k 
sp
ee
d
G
ri
p
 s
tr
en
g
th
O
R
(9
5%
 C
I)
P
 v
al
ue
E
M
(9
5%
 C
I)
P
 v
al
ue
E
M
(9
5%
 C
I)
P
 v
al
ue
E
M
(9
5%
 C
I)
P
 v
al
ue
E
M
(9
5%
 C
I)
P
 v
al
ue
E
M
(9
5%
 C
I)
P
 v
al
ue
 
 S
ex
 
 Fe
m
al
e
R
ef
er
en
t
–
14
.4
7
(1
0.
81
 t
o 
14
.3
9)
–
54
.8
4
(5
3.
37
 t
o 
56
.3
3)
–
15
.1
9
(1
4.
70
 t
o 
15
.7
1)
–
0.
94
(0
.9
1 
to
 0
.9
6)
–
32
.4
2
(3
1.
56
 t
o 
33
.2
7)
–
 
 M
al
e
1.
10
(0
.8
6 
to
 1
.4
2)
0.
45
1
9.
91
(8
.5
5 
to
 1
1.
47
)
<
0.
00
1
56
.7
2
(5
5.
21
 t
o 
58
.2
2)
0.
00
1
13
.4
3
(1
2.
98
 t
o 
13
.9
0)
<
0.
00
1
1.
05
(1
.0
3 
to
 1
.0
8)
<
0.
00
1
44
.7
4
(4
2.
88
 t
o 
45
.6
0)
<
0.
00
1
 
 A
ge
 
 
1.
08
(1
.0
7 
to
 1
.0
9)
<
0.
00
1
0.
03
9*
0.
00
2
<
0.
00
1
−
0.
31
2*
0.
02
5
<
0.
00
1
0.
00
9*
0.
00
1
<
0.
00
1
−
0.
00
7*
0.
00
1
<
0.
00
1
−
0.
41
7*
0.
01
5
<
0.
00
1
 
 E
d
uc
at
io
na
l l
ev
el
 
co
m
p
le
te
d
 
 S
om
e 
ed
uc
at
io
n
R
ef
er
en
t
–
9.
18
(7
.3
7 
to
 1
1.
44
)
–
56
.5
9
(5
4.
45
 t
o 
58
.7
2)
–
13
.6
7
(1
3.
04
 t
o 
14
.3
4)
–
1.
03
(1
.0
0 
to
 1
.0
7)
–
39
.7
3
(3
8.
51
 t
o 
40
.9
5)
–
 
 N
o 
ed
uc
at
io
n
0.
94
(0
.5
9 
to
 1
.5
3)
0.
81
4
13
.4
5
(1
2.
14
 t
o 
14
.9
1)
<
0.
00
1
54
.9
8
(5
3.
85
 t
o 
56
.1
1)
0.
11
3
14
.9
3
(1
4.
54
 t
o 
15
.3
2)
<
0.
00
1
0.
96
(0
.9
4 
to
 0
.9
8)
<
0.
00
1
37
.4
3
(3
6.
77
 t
o 
38
.0
8)
<
0.
00
1
 
 M
ar
ita
l s
ta
tu
s
M
ar
rie
d
 o
r 
co
ha
b
iti
ng
R
ef
er
en
t
–
10
.3
4
(9
.0
0 
to
 1
1.
88
)
–
56
.4
8
(5
5.
06
 t
o 
57
.9
0)
–
14
.0
3
(1
3.
59
 t
o 
14
.4
8)
–
1.
01
(0
.9
8 
to
 1
.0
3)
–
38
.9
3
(3
8.
12
 t
o 
39
.7
5)
–
W
id
ow
ed
, 
d
iv
or
ce
d
, s
in
gl
e
1.
19
(0
.9
1 
to
 1
.5
7)
0.
20
4
11
.9
5
(1
0.
21
 t
o 
13
.9
7)
0.
01
9
55
.0
9
(5
3.
43
 t
o 
56
.7
5)
0.
04
3
14
.5
5
(1
4.
01
 t
o 
15
.1
0)
0.
01
9
0.
98
(0
.9
5 
to
 1
.0
1)
0.
01
8
38
.2
2
(3
7.
27
 t
o 
39
.1
8)
0.
07
1
W
ea
lth
 (q
ui
nt
ile
s)
 
 5
R
ef
er
en
t
–
11
.3
(9
.6
8 
to
 1
3.
19
)
–
60
.7
5
(6
9.
15
 t
o 
62
.3
6)
–
14
.6
3
(1
4.
11
 t
o 
15
.1
7)
–
1.
00
(0
.9
7 
to
 1
.0
2)
–
40
.7
0
(3
9.
77
 t
o 
41
.6
2)
–
 
 
 
 4
0.
85
(0
.6
0 
to
 1
.2
1)
0.
35
7
10
.6
7
(9
.0
2 
to
 1
2.
62
)
0.
45
2
58
.0
7
(5
6.
35
 t
o 
59
.7
9)
0.
00
1
14
.1
2
(1
3.
59
 t
o 
14
.6
8)
0.
04
4
1.
03
(1
.0
0 
to
 1
.0
6)
0.
01
39
.0
5
(3
8.
06
 t
o 
40
.0
4)
0.
00
1
 
 
 
 3
0.
61
(0
.4
1 
to
 0
.8
9)
0.
01
1
11
.2
9
(9
.5
2 
to
 1
3.
39
)
0.
99
0
55
.3
1
(5
3.
54
 t
o 
57
.0
7)
<
0.
00
1
14
.0
1
(1
3.
37
 t
o 
14
.5
7)
0.
01
5
1 (0
.9
7 
to
 1
.0
3)
0.
97
9
38
.5
1
(3
7.
50
 t
o 
39
.5
2)
<
0.
00
1
 
 
 
 2
1.
04
(0
.7
3 
to
 1
.4
7)
0.
84
6
11
.2
5
(9
.5
1 
to
 1
3.
32
)
0.
95
7
54
.8
9
(5
3.
15
 t
o 
56
.6
2)
<
0.
00
1
14
.4
(1
3.
85
 t
o 
14
.9
6)
0.
36
6
0.
99
(0
.9
6 
to
 1
.0
2)
0.
62
3
37
.9
6
(3
6.
96
 t
o 
38
.9
5)
<
0.
00
1
 
 
 
 1
1.
20
(0
.8
6 
to
 1
.6
7)
0.
23
4
11
.0
8
(9
.3
8 
to
 1
3.
07
)
0.
79
5
49
.9
1
(4
8.
17
 t
o 
51
.6
5)
<
0.
00
1
14
.1
8
(1
3.
73
 t
o 
14
.8
5)
0.
18
5
0.
96
(0
.9
3 
to
 0
.9
9)
0.
01
4
36
.6
8
(3
5.
67
 t
o 
37
.6
8)
<
0.
00
1
 
 N
o 
of
 c
on
d
iti
on
s
 
 –
1.
52
(1
.2
7 
to
 1
.8
3)
<
0.
00
1
<
0.
00
1
<
0.
00
1
0.
58
5
0.
00
1
0.
88
5
M
ul
tim
or
b
id
ity
 
ca
te
go
ry
N
o 
m
ul
tim
or
b
id
ity
R
ef
er
en
t
–
9.
75
(8
.6
9 
to
 1
0.
94
)
–
56
.6
4
(5
5.
52
 t
o 
57
.7
8)
14
.1
5
(1
3.
80
 t
o 
14
.5
1)
–
0.
99
(0
.9
7 
to
 1
.0
0)
–
38
.8
5
(3
8.
21
 t
o 
39
.4
9)
 
 
 
 C
on
co
rd
an
t
0.
73
(0
.4
7 
to
 1
.1
4)
0.
17
7
11
.6
7
(9
.6
6 
to
 1
4.
08
)
0.
07
5
55
.9
1
(5
3.
87
 t
o 
57
.9
4)
0.
50
9
14
.4
6
(1
3.
82
 t
o 
15
.1
4)
0.
38
4
1 (0
.9
6 
to
 1
.0
3)
0.
52
6
38
.8
9
(3
7.
72
 t
o 
40
.0
6)
0.
25
7
 
 
 
 D
is
co
rd
an
t
0.
99
(0
.6
0 
to
 0
.6
3)
0.
97
0
12
.0
7
(9
.7
2 
to
 1
5.
00
)
0.
06
6
54
.8
0
(5
2.
40
 t
o 
57
.2
0)
0.
15
9
14
.2
4
(1
3.
48
 t
o 
15
.0
5)
0.
82
8
1 (0
.9
6 
to
 1
.0
4)
0.
45
8
37
.9
9
(3
6.
61
 t
o 
39
.3
8)
0.
94
6
*B
et
a 
va
lu
es
 w
ith
 S
E
s.
D
A
S
, D
is
ab
ili
ty
 A
ss
es
sm
en
t 
S
ch
ed
ul
e;
 E
M
, e
st
im
at
ed
 m
ar
gi
na
l m
ea
n.
copyright.
 o
n
 M
ay 28, 2020 at Barnes Library M
edical School. Protected by
http://gh.bmj.com/
BM
J G
lob Health: first published as 10.1136/bmjgh-2019-002096 on 29 March 2020. Downloaded from 
12 Odland ML, et al. BMJ Global Health 2020;5:e002096. doi:10.1136/bmjgh-2019-002096
BMJ Global Health
Figure 2 Proportions and overlap between people with 
non- communicable diseases, mental health conditions and 
communicable diseases.
system can deal with this increasing burden of disease 
and its downstream consequences.
The mismatch between prevalence of multimorbidity 
and research output in LMICs (only 5% of multimor-
bidity research originates from LMICs) is well known.6 18 
This study contributes to filling that knowledge gap, yet 
further research on the clusters of multimorbidity, their 
associations with adverse outcomes and health system 
solutions to prevent and manage multimorbidity is 
urgently required. Data collection that extends beyond 
a priori defined morbidities commonly seen in high- 
incomes settings, to include locally determined and 
prioritised conditions must increasingly drive this area of 
research.
This study has several limitations. Even though multi-
morbidity prevalence was high, the number of conditions 
evaluated was limited, and it is likely that our multimor-
bidity prevalence estimates are conservative. Moreover, 
many of the NCDs (cancer, heart and respiratory disease) 
and HIV in our study relied on self- report of a diagnosis 
from a medical professional. However, many people in 
this population lack the financial resources or awareness 
to seek medical care for their conditions, further under-
estimating true prevalence and perhaps overestimating 
multimorbidity prevalence in people in the high income 
category. There is especially likely to be under- reporting 
of HIV in our study, due to the stigma associated with the 
condition. While we relied mostly on self- reported diag-
noses in this study, restricting our analysis to objective 
measurements did not substantially change our results 
(online supplementary appendix table 3). We were not 
able to capture information on all chronic conditions, 
for example, osteoarthritis or visual impairment, in our 
survey, meaning that our estimates should be considered 
a lower bound on the true prevalence of multimorbidity 
in this population. However, we intentionally captured as 
broad spectrum of conditions as possible, and reported 
on 11 common conditions, similar to that seen in other 
studies in similar settings.12
This study is also cross- sectional, limiting our ability 
to assess causation. Nonetheless, longitudinal studies in 
high- income countries have pointed to a causal relation-
ship between multimorbidity and outcomes similar to 
those assessed here.60 61 Finally, participants were selected 
only from one area of Burkina Faso and hence our find-
ings may not generalise nationally or internationally.
ConClusIons
Burkina Faso is one of the poorest countries in the world, 
yet these findings show that chronic multimorbidity is 
already highly prevalent and associated with adverse 
health conditions. This research adds to a growing body 
of literature that highlights multimorbidity as a global 
health issue of major significance. Investment is needed 
by researchers, development agencies and national 
governments to prioritise understanding of multimor-
bidity in lower income settings, and to develop and test 
interventions to prevent multimorbidity and mitigate 
their adverse consequences.
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